iridium radioisotopes has been researched along with Cancer of Prostate in 120 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (5.83) | 18.7374 |
1990's | 23 (19.17) | 18.2507 |
2000's | 57 (47.50) | 29.6817 |
2010's | 29 (24.17) | 24.3611 |
2020's | 4 (3.33) | 2.80 |
Authors | Studies |
---|---|
Chang, AJ; Frank, CH; Kishan, AU; Lyu, Q; Park, SJ; Ramesh, P; Ruan, D; Sheng, K; Venkat, PS | 1 |
Buchser, D; Cacicedo, J; Casquero, F; Espinosa, J; Gomez-Iturriaga, A; Gonzalez, A; Martinez-Indart, L; Mayrata, E; Minguez, P; Perez, F; San Miguel, I; Suarez, F | 1 |
Fu, Z; Jiang, C; Jiang, Y; Liu, T; Qin, W; Shi, K; Sun, Q; Wang, F; Wu, P; Ye, Z | 1 |
Arnau, GM; Caramia, F; Gamell, C; Gulati, T; Haupt, Y; Huang, C; Keam, SP; Kleifeld, O; Neeson, PJ; Schittenhelm, RB; Williams, SG | 1 |
Enger, SA; Keyes, R; Mao, X; Pineau, J | 1 |
Davis, IR; Dayes, IS; Gilbert, J; Julian, JA; Levine, MN; Parpia, S; Sathya, J | 1 |
Bucci, J; Cutajar, D; Guatelli, S; Howie, A; Petasecca, M; Poder, J; Rosenfeld, A | 1 |
Beyer, B; Carl, CO; Frenzel, T; Graefen, M; Krüll, A; Löser, A; Löser, B; Nagaraj, Y; Petersen, C; Schwarz, R | 1 |
Hannoun-Lévi, JM; Peiffert, D | 1 |
Karimi Jashni, S; Mahdavi, SR; Meigooni, AS; Safigholi, H; Sardari, D | 1 |
Alonzi, R; Bryant, L; Hoskin, P; Hughes, R; Lowe, G; Ostler, P; Rojas, A | 1 |
Adams, QE; Breitbach, EK; Enger, SA; Flynn, RT; Kim, Y; Li, X; Rockey, WR; Wu, X; Xu, J | 1 |
Boladeras, A; Díaz, A; Ferrer, F; Guedea, F; Gutierrez, C; Martinez, E; Pera, J; Pino, F; Polo, A; Santorsa, L; Suarez, JF | 1 |
Alonzi, R; Dankulchai, P; Díez, P; Hoskin, PJ; Hughes, R; Lowe, G; Mullassery, V; Ostler, P | 1 |
Gotovchikova, MY; Iliin, ND; Kanaev, SV; Novikov, RV; Novikov, SN | 1 |
Garmash, SV; Isaev, TK; Kravtsov, IB; Panshin, GA; Pavlov, AY; Solodky, VA; Tsybulsky, AD | 1 |
Franich, RD; Haworth, A; Millar, JL; Panettieri, V; Smith, RL | 1 |
Beld, E; Lagendijk, JJ; Moerland, MA; Seevinck, PR; Viergever, MA | 1 |
Gustafson, GS; Krauss, DJ; Limbacher, A; Martinez, AA; Mitchell, B; Sebastian, E; Ye, H | 1 |
Furukawa, S; Hoshino, Y; Katoh, H; Kurotaki, K; Nakano, T; Noda, S; Suzuki, Y | 1 |
Chiang, PH; Fang, FM; Huang, HY; Wang, CJ; Wang, YM | 1 |
Boda-Heggemann, J; Ehmann, M; Hermann, B; Köhler, FM; Küpper, B; Lohr, F; Riesenacker, N; Wenz, F; Wertz, H | 1 |
Choo, R; Furutani, KM; Gold, DG; Hebl, JR; Macdonald, OK; McLaren, RH; Mynderse, LA; Pisansky, TM; Wilson, TM | 1 |
Boreham, D; Dayes, IS; Julian, J; Sathya, J; Schnarr, K | 1 |
Baba, S; Hayakawa, K; Ishiyama, H; Kitano, M; Kotani, S; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K; Uemae, M | 1 |
Ares, C; Bieri, S; Dipasquale, G; Khan, H; Miralbell, R; Nouet, P; Ozsoy, O; Pampallona, S; Popowski, Y; Rouzaud, M | 1 |
Anton, M; Hackel, T; Hermann, RM; Hess, CF; Selbach, HJ; Vorwerk, H; Wagner, D | 1 |
Demanes, J; Ghilezan, M; Gustafson, GS; Martinez, AA; Schour, L; Vargas, C | 1 |
Izumi, K; Konaka, H; Kumano, T; Mizokami, A; Namiki, M; Narimoto, K; Nohara, T; Shigehara, K; Yasuhide, K; Yoshifumi, K | 1 |
Ghilezan, M; Gonzalez, J; Gustafson, G; Kernen, K; Kestin, L; Krauss, D; Martinez, AA; Shetty, S; Vicini, F; Ye, H | 1 |
Dumas, I; Haie-Meder, C; Martelli, H; Mazeron, R; Oberlin, O | 1 |
Akimoto, T; Ebara, T; Ishikawa, H; Ito, K; Kato, H; Miyakubo, M; Nakano, T; Okamoto, M; Suzuki, K; Takahashi, T; Tamaki, T; Yamamoto, T | 1 |
Bryant, L; Cladd, H; Hoskin, P; Hughes, R; Lowe, G; Milner, J; Ostler, P; Rojas, A | 1 |
Coalter, G; Haughey, A; Mugabe, K | 1 |
Kropf, S; Lüdemann, L; Mohnike, K; Ricke, J; Seidensticker, M; Wust, P; Wybranski, C | 1 |
Fujii, T; Hara, R; Hiratsuka, J; Jo, Y; Miyaji, Y; Nagai, A; Yoden, E; Yokoyama, T | 1 |
Lilleby, W; Raabe, NK; Tafjord, G | 1 |
Budiharto, T; Corn, BW; Davits, RJ; de Kruijf, WJ; Haustermans, K; Hol, S; Neustadter, D; Oyen, R; Poortmans, PM; Van den Bergh, L; Venselaar, JL; Verstraete, J; Wijsman, BP | 1 |
Borroni, M; Carrara, M; Cerrotta, A; Fallai, C; Gambarini, G; Grisotto, S; Maucione, A | 1 |
Djukic, V; Eble, MJ; Heidenreich, A; Holy, R; Klotz, J; Pfister, D; Pinkawa, M; Piroth, MD | 1 |
Enger, SA; Fisher, DR; Flynn, RT | 1 |
Gabor, S; Hackl, A; Mayer, R; Prettenhofer, U; Stranzl, H; Wurzinger, G | 1 |
Gonzalez, J; Gustafson, G; Kearney, D; Kestin, L; Martinez, A; Spencer, W; Vicini, FA | 1 |
Dokiya, T; Momma, T; Saito, S; Yorozu, A | 1 |
Brenner, PC; Cross, P; Duval, PJ; Jagavkar, RS; Kooner, R; Martland, J; O'Neill, GF; Saalfeld, J; Stevens, MJ; Stricker, PD | 1 |
Anagnostopoulos, G; Baltas, D; Baras, P; Karaiskos, P; Kipouros, P; Kozicki, M; Papagiannis, P; Sakelliou, L; Sandilos, P; Seimenis, I | 1 |
Anagnostopoulos, G; Baltas, D; Geretschlaeger, A; Martin, T; Papagiannis, P; Tselis, N; Zamboglou, N | 1 |
Lee, WR; Moughan, J; Owen, JB; Zelefsky, MJ | 1 |
Hirokawa, Y | 1 |
Chiang, PH; Chuang, YC; Fang, FM; Jong, WC; Wang, HJ; Yu, TJ | 1 |
Dogan, N; Glasgow, GP; Mohideen, N | 1 |
Fujisawa, M; Hiratsuka, J; Imajo, Y; Jo, Y; Nagase, N; Yoshida, K | 1 |
Bucci, J; Duggan, L; Kron, T | 1 |
Brandberg, Y; Häggarth, L; Hellström, M; Nilsson, S; Wahlgren, T | 1 |
Fujii, T; Fujisawa, M; Hiratsuka, J; Jo, Y; Takenaka, A | 1 |
Brinkmann, DH; Davis, BJ; Herman, MG; Kline, RW; Kruse, JJ; LaJoie, WN; Pisansky, TM; Schwartz, DJ | 1 |
Chawla, R; Joneja, OP; Popowski, Y; Zilio, VO | 1 |
Cosset, JM; Mettler, F; Pinillos-Ashton, L | 1 |
Deneufbourg, JM; Lenaerts, E; Nickers, P; Thissen, B | 1 |
Bertermann, H; de la Rosette, JJ; Hammer, J; Kolkman-Deurloo, IK; Kovács, G; Loch, T; Pötter, R | 1 |
Khaksar, SJ; Laing, RW; Langley, SE | 1 |
Akimoto, T; Ito, K; Kashiwagi, B; Katoh, H; Nakano, T; Noda, SE; Yamamoto, T | 1 |
Akimoto, T; Harashima, K; Ito, K; Nakano, T; Nakayama, Y; Niibe, H; Noda, SE; Saitoh, J; Sakurai, H; Suzuki, K; Yamamoto, T | 1 |
Deneufbourg, JM; Jansen, N; Nickers, P; Thissen, B | 1 |
Asadpour, B; Borchers, H; Eble, MJ; Fischedick, K; Gagel, B; Jakse, G; Pinkawa, M; Piroth, MD; Treusacher, P | 1 |
Hsu, IC; Inoue, T; Lessard, E; Pouliot, J; Shiomi, H; Sumida, I; Yoshioka, Y | 1 |
Akimoto, T; Katoh, H; Kitamoto, Y; Nakano, T; Shioya, M; Shirai, K | 1 |
Baltas, D; Giannouli, S; Lymperopoulou, G; Milickovic, N; Papagiannis, P; Sakelliou, L | 1 |
Komatsu, K; Koshida, K; Mizokami, A; Namiki, M; Shigehara, K | 1 |
Maloney, KE; Moul, JW; Sevilla, DW; Tseng, TY | 1 |
Dokiya, T; Momma, T; Murai, M; Saito, S; Toya, K; Yorozu, A | 1 |
Akimoto, T; Harada, K; Katoh, H; Kitamoto, Y; Nakano, T; Shirai, K; Tamaki, T | 1 |
Inoue, T; Isohashi, F; Kato, M; Kawaguchi, Y; Konishi, K; Nakamura, S; Oh, RJ; Shiomi, H; Sumida, I; Suzuki, O; Tanaka, E; Yoshioka, Y | 1 |
Coppens, L; de Leval, J; Deneufbourg, JM; Jansen, N; Nickers, P | 1 |
Dobbins, T; Fogarty, GB; Haddad, RL; Izard, MA; Katelaris, P; Rinks, A | 1 |
Bownes, P; Bryant, L; Bullard, J; Chin, YS; Hoskin, PJ; Ostler, P | 1 |
Albertsson, P; Edgren, M; Ekelund, AM; Lennernäs, B; Levitt, S; Lundberg, LM; Nilsson, S; Ullen, A | 1 |
Buron, C; Chauveinc, L; Cosset, JM; Delannes, M; Flam, T; Guerif, S; Le Vu, B; Livartowski, A; Peiffert, D; Pommier, P; Salem, N | 1 |
Chaswal, V; Henderson, DL; Thomadsen, BR; Yoo, S | 1 |
Chang, TC; Hanyu, N; Karasawa, K; Kuga, G; Yoshida, D | 1 |
Castellanos, E; Cohn-Cedermark, G; Fowler, J; Hellström, M; Kälkner, KM; Levitt, S; Lundell, M; Nilsson, J; Nilsson, S; Ryberg, M; Wahlgren, T; Zimmerman, R | 1 |
Edmundson, G; Gonzalez, J; Gustafson, G; Hollander, J; Martinez, A; Ohanian, N; Spencer, W; Stromberg, J; Vicini, F; Yan, Di | 1 |
Court, B; Gerbaulet, A; Haie-Meder, C; Lartigau, E; Perrin, JL; Wibault, P | 1 |
Flamant, F; Gerbaulet, A; Gruner, M; Habrand, JL; Haie-Meder, C; Martelli, H; Revillon, Y; Terrier-Lacombe, MJ; Valayer, J | 1 |
Bagshaw, MA; Ben-Yosef, R; Fessenden, P; Goffinet, DR; Kapp, DS; Prionas, SD | 1 |
Benson, R; Brabbins, D; Diokno, A; Edmundson, G; Garton, G; Gonzalez, J; Martinez, A; Schray, M; Stromberg, J; Zincke, H | 1 |
Forman, JD; Porter, AT | 1 |
Yu, Y | 1 |
Hahn, EW; Hildenbrand, D; Peschke, P; Wolber, G; Zuna, I | 1 |
Feldmann, HJ; Hartung, R; Hofmann, R; Kneschaurek, P; Molls, M; Paul, R; Schwarzer, JU; Stepan, R | 1 |
Aldenborg, F; Borghede, G; Hedelin, H; Holmäng, S; Johansson, KA; Mercke, C; Pettersson, S; Sernbo, G; Wallgren, A | 1 |
Borghede, G; Hedelin, H; Holmäng, S; Johansson, KA; Mercke, C; Sernbo, G | 1 |
Budach, V; Dinges, S; Loening, SA | 1 |
Budach, V; Deger, S; Dinges, S; Hinkelbein, W; Loening, SA; Roigas, J; Schnorr, D; Turk, I | 1 |
Gottesman, JE; Gribble, M; Hatton, J; Mate, TP; Van Hollebeke, L | 1 |
Boehmer, D; Budach, V; Deger, S; Dietel, M; Dinges, S; Hinkelbein, W; Koswig, S; Loening, SA; Schnorr, D; Wiegel, T | 1 |
Andreopoulos, D; Krenkel, B; Piatkowiak, M; Schleicher, UM; Wolff, JM | 1 |
Beauduin, M; Coppers, L; Darimont, M; de Leval, J; Deneufbourg, J; Nickers, P | 1 |
Amols, HI; Cohen, GN; Zaider, M | 1 |
Albert, A; Beauduin, M; Coppens, L; de Leval, J; Deneufbourg, JM; Nickers, P; Sabatier, J | 1 |
Dokiya, T; Momma, T; Murai, M; Saito, S | 1 |
Inomata, T; Inoue, K; Inoue, Y; Karashima, T; Kariya, S; Kasahara, K; Shuin, T; Yoshida, S | 2 |
Austin, PA; Baghdassarian, R; Cherlow, JM; Espinoza-Ferrel, T; Ingram, JE; Londrc, A; Perley, JE; Perley, JM; Puthawala, AA; Sawyer, DE; Shanberg, AM; Syed, AM; Wachs, BH | 1 |
Furihata, M; Inoue, K; Kariya, S; Kasahara, K; Shuin, T; Taguchi, T; Yoshida, S | 1 |
Armour, EP; Brenner, DJ; Edmundson, GK; Martinez, AA; Mitchell, C; Thames, HD | 1 |
Marinelli, D; Puthawala, A; Sawyer, DE; Shanberg, AM; Syed, N; Tansey, LA | 1 |
Bush, S; Khan, K; Stidley, C; Thompson, W | 1 |
Austin, P; Baghdassarian, R; Cherlow, J; Perley, J; Puthawala, A; Sawyer, D; Shanberg, A; Syed, AM; Tansey, L; Wachs, B | 1 |
Braun, J; Hofmann, R; Kneschaurek, P; Lindner, A; Lukas, P; Schwarzer, JU | 1 |
Donnelly, BJ; McPhee, MS; Pedersen, JE; Porter, AT | 1 |
Bagshaw, MA; Cox, RS; Freiha, F; Goffinet, DR; Kapp, DS; Prionas, SD | 1 |
Brosman, SA | 1 |
Porter, AT | 1 |
Porter, AT; Scrimger, JW | 1 |
Benson, RC; Brindle, JS; Diokno, A; Edmundson, G; Gonzalez, J; Martinez, A; Schray, M; Zincke, H | 1 |
Bertermann, H | 1 |
Ali, MM; Hackler, RH; Klein, FA; Marks, SE | 1 |
Pocha, JS; Porter, AT; Scrimger, JW | 1 |
De Laroche, G; Gerard, JP; Koonsilin, L; Mornex, F; Romestaing, P | 1 |
12 review(s) available for iridium radioisotopes and Cancer of Prostate
Article | Year |
---|---|
[Development and perspectives of brachytherapy in France].
Topics: Brachytherapy; Cancer Care Facilities; Cesium Radioisotopes; Female; Forecasting; France; Health Services Accessibility; Hospitals, Military; Hospitals, Public; Hospitals, University; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Neoplasms; Practice Patterns, Physicians'; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Vaginal Neoplasms | 2013 |
High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer.
Topics: Brachytherapy; Dose Fractionation, Radiation; Humans; Iridium Radioisotopes; Male; Patient Selection; Prostatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Treatment Outcome | 2008 |
[Brachytherapy in paediatric sarcoma].
Topics: Brachytherapy; Child; Female; Genital Neoplasms, Female; Humans; Iridium Radioisotopes; Male; Models, Anatomic; Prostatic Neoplasms; Radiotherapy Dosage; Rhabdomyosarcoma; Sarcoma; Sex Factors; Urinary Bladder Neoplasms; Vaginal Neoplasms | 2011 |
[Brachytherapy for prostate neoplasms].
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome | 2002 |
[Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Relative Biological Effectiveness | 2003 |
Fertility after prostate brachytherapy.
Topics: Brachytherapy; Fertility; Humans; Iridium Radioisotopes; Male; Postoperative Period; Prostatic Neoplasms; Radiotherapy Dosage | 2005 |
[Brachytherapy in prostatic adenocarcinoma].
Topics: Adenocarcinoma; Brachytherapy; Combined Modality Therapy; Gold Radioisotopes; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Lymph Node Excision; Male; Prognosis; Prostatic Neoplasms; Survival Rate | 1994 |
Prostate brachytherapy. An overview.
Topics: Brachytherapy; Gold Radioisotopes; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Palladium; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Ytterbium | 1993 |
[Combined iridium 192 afterloading therapy of prostate carcinoma].
Topics: Brachytherapy; Combined Modality Therapy; Humans; Iridium Radioisotopes; Male; Neoplasm Staging; Prognosis; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies | 1997 |
Followup prostate biopsy in patients with carcinoma of the prostate treated by 192iridium template irradiation plus supplemental external beam radiation.
Topics: Aged; Biopsy; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostate; Prostatic Neoplasms; Radiotherapy | 1992 |
Is radiotherapy of use in stage C prostate cancer?
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms | 1989 |
Remote afterloading in prostatic cancer.
Topics: Brachytherapy; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Prostatic Neoplasms | 1989 |
26 trial(s) available for iridium radioisotopes and Cancer of Prostate
Article | Year |
---|---|
Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage | 2020 |
Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate.
Topics: Brachytherapy; Cause of Death; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
[Complications and effectiveness of treatment of patients with locally advanced prostate cancer after combined radiotherapy and radical prostatectomy with postoperative radiotherapy].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Erectile Dysfunction; Humans; Incidence; Intraoperative Period; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Russia; Treatment Outcome; Urinary Incontinence | 2015 |
Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Grading; Non-Randomized Controlled Trials as Topic; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Risk; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Urination Disorders | 2017 |
High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Topics: Aged; Brachytherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Palladium; Prostatic Neoplasms; Radiation Injuries; Radioisotopes; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2010 |
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alpha Particles; Beta Particles; Brachytherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk | 2011 |
High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Brachytherapy; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Organs at Risk; Prostate-Specific Antigen; Prostatic Neoplasms; Rectum; Urethra | 2012 |
Patient positioning based on a radioactive tracer implanted in patients with localized prostate cancer: a performance and safety evaluation.
Topics: Fiducial Markers; Gold; Humans; Iridium Radioisotopes; Male; Movement; Patient Positioning; Prostatic Neoplasms; Radionuclide Imaging; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided | 2013 |
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Aged, 80 and over; Brachytherapy; Disease-Free Survival; Humans; Iridium Radioisotopes; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2003 |
High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Feasibility Studies; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy Dosage | 2004 |
High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Brachytherapy; Combined Modality Therapy; Cystitis; Disease-Free Survival; Dose Fractionation, Radiation; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Proctitis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy, High-Energy; Treatment Outcome | 2004 |
Does inverse planning applied to Iridium192 high dose rate prostate brachytherapy improve the optimization of the dose afforded by the Paris system?
Topics: Adenocarcinoma; Brachytherapy; Dose Fractionation, Radiation; Humans; Imaging, Three-Dimensional; Iridium Radioisotopes; Male; Patient Care Planning; Prostatic Neoplasms; Radiation Injuries; Radiometry; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Rectum; Surveys and Questionnaires; Urethra | 2006 |
Four year clinical statistics of iridium-192 high dose rate brachytherapy.
Topics: Aged; Aged, 80 and over; Brachytherapy; Disease-Free Survival; Humans; Iridium Radioisotopes; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Radiotherapy Dosage; Survival Rate; Time Factors | 2006 |
192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome | 2006 |
High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study.
Topics: Aged; Analysis of Variance; Brachytherapy; Fecal Incontinence; France; Gastrointestinal Hemorrhage; Health Care Costs; Health Status; Hospitalization; Humans; Iridium Radioisotopes; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Urination Disorders | 2007 |
Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Topics: Adenocarcinoma; Aged; Brachytherapy; Disease-Free Survival; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Treatment Outcome | 2007 |
Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Ultrasonography, Interventional | 1995 |
Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Brachytherapy; Combined Modality Therapy; Hot Temperature; Humans; Hyperthermia, Induced; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Prostheses and Implants; Retrospective Studies; Thermometers | 1994 |
Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Survival Rate | 1994 |
Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma.
Topics: Aged; Brachytherapy; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Penile Erection; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Treatment Outcome; Urination Disorders | 1997 |
High-dose rate iridium192 afterloading therapy in combination with external beam irradiation for localized prostate cancer.
Topics: Adenocarcinoma; Aged; Brachytherapy; Carcinoma in Situ; Combined Modality Therapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Dosage; Treatment Outcome | 1997 |
High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial.
Topics: Adenocarcinoma; Aged; Biopsy; Brachytherapy; Colitis, Ulcerative; Colostomy; Diabetes Complications; Feasibility Studies; Fistula; Follow-Up Studies; Humans; Iridium Radioisotopes; Laparoscopy; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Dosage; Rectal Fistula; Risk Factors; Urethral Diseases | 1998 |
Brachytherapy for prostate cancer in Japan.
Topics: Aged; Aged, 80 and over; Brachytherapy; Humans; Iridium Radioisotopes; Japan; Male; Middle Aged; Palladium; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Survival Analysis; Treatment Outcome | 2001 |
Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Topics: Aged; Aged, 80 and over; Aneuploidy; Brachytherapy; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 8; Dose-Response Relationship, Radiation; Humans; In Situ Hybridization, Fluorescence; Iridium Radioisotopes; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2001 |
82 other study(ies) available for iridium radioisotopes and Cancer of Prostate
Article | Year |
---|---|
Analytical HDR prostate brachytherapy planning with automatic catheter and isotope selection.
Topics: Brachytherapy; Catheters; Humans; Iridium Radioisotopes; Male; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2023 |
Methodology of dose calculation for external beam radiation combined with high dose rate brachytherapy in the era of 3-dimensional treatment planning system.
Topics: Algorithms; Brachytherapy; Carcinoma; Dose Fractionation, Radiation; Female; Humans; Iridium Radioisotopes; Male; Nasopharyngeal Neoplasms; Prostatic Neoplasms; Radiation Dosage; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2020 |
Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue.
Topics: Dose-Response Relationship, Radiation; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Proteomics; Radiometry; Transcription, Genetic | 2018 |
RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
Topics: Brachytherapy; Colon, Sigmoid; Deep Learning; Female; Humans; Iridium Radioisotopes; Male; Monte Carlo Method; Neural Networks, Computer; Organs at Risk; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Rectum; Retrospective Studies; Urinary Bladder; Uterine Cervical Neoplasms | 2020 |
HDR brachytherapy in vivo source position verification using a 2D diode array: A Monte Carlo study.
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Monte Carlo Method; Phantoms, Imaging; Prostatic Neoplasms; Radiotherapy Dosage | 2018 |
Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Risk Factors | 2019 |
An analytical model to determine interseed attenuation effect in low-dose-rate brachytherapy.
Topics: Algorithms; Brachytherapy; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Models, Theoretical; Monte Carlo Method; Phantoms, Imaging; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2013 |
High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.
Topics: Aged; Brachytherapy; Dose-Response Relationship, Radiation; Gastrointestinal Diseases; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Rectum; Urethra; Urologic Diseases | 2014 |
Interstitial rotating shield brachytherapy for prostate cancer.
Topics: Brachytherapy; Catheters; Equipment Design; Gadolinium; Humans; Iridium Radioisotopes; Male; Monte Carlo Method; Needles; Nickel; Platinum Compounds; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Rectum; Time Factors; Titanium; Urethra; Urinary Bladder | 2014 |
External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Cohort Studies; Dose Fractionation, Radiation; Humans; Iridium Radioisotopes; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Treatment Outcome | 2014 |
Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer.
Topics: Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Urethra; Urethral Stricture | 2014 |
[High-dose brachytherapy for prostate cancer in real time using 192-IR (specifics of dosimetric planning)].
Topics: Aged; Brachytherapy; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Treatment Outcome | 2015 |
A method for verification of treatment delivery in HDR prostate brachytherapy using a flat panel detector for both imaging and source tracking.
Topics: Brachytherapy; Catheters; Equipment Design; Fiducial Markers; Humans; Iridium Radioisotopes; Male; Models, Anatomic; Phantoms, Imaging; Prostate; Prostatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Water | 2016 |
Monte Carlo study of the impact of a magnetic field on the dose distribution in MRI-guided HDR brachytherapy using Ir-192.
Topics: Brachytherapy; Computer Simulation; Humans; Iridium Radioisotopes; Magnetic Fields; Magnetic Resonance Imaging; Male; Monte Carlo Method; Phantoms, Imaging; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Image-Guided; Software | 2016 |
Clinical application of the Fricke-glucomannan gel dosimeter for high-dose-rate (192)Ir brachytherapy.
Topics: Absorption; Brachytherapy; Calibration; Gels; Humans; Iridium Radioisotopes; Magnetic Resonance Imaging; Male; Mannans; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Reproducibility of Results; Thermoluminescent Dosimetry | 2008 |
Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Topics: Aged; Brachytherapy; Disease-Free Survival; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Gastrointestinal Diseases; Humans; Iridium Radioisotopes; Male; Male Urogenital Diseases; Proportional Hazards Models; Prostatic Neoplasms; Radiotherapy; Radiotherapy, Conformal; Retrospective Studies | 2008 |
Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT.
Topics: Brachytherapy; Cone-Beam Computed Tomography; Dose Fractionation, Radiation; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Iridium Radioisotopes; Male; Motion; Prostatic Neoplasms; Radiation Oncology; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Reproducibility of Results; Treatment Outcome | 2008 |
Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Humans; Iridium Radioisotopes; Male; Predictive Value of Tests; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy; Regression Analysis; T-Lymphocytes, Cytotoxic | 2009 |
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Brachytherapy; Flutamide; Humans; Iridium Radioisotopes; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Radiation Injuries; Radiography; Radiotherapy; Radiotherapy Dosage; Rectum; Regression Analysis; Relative Biological Effectiveness; Tumor Burden; Urethra; Urogenital System | 2009 |
Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Topics: Aged; Androgen Antagonists; Brachytherapy; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Humans; Iridium Radioisotopes; Magnetic Resonance Imaging, Interventional; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Urination Disorders | 2009 |
In vivo dosimetry in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer--a phantom study.
Topics: Alanine; Brachytherapy; Electron Spin Resonance Spectroscopy; Humans; Iridium Radioisotopes; Male; Phantoms, Imaging; Prostatic Neoplasms; Radiation Dosage; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Uncertainty; Urethra | 2009 |
Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy.
Topics: Aged; Aged, 80 and over; Brachytherapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radioisotope Teletherapy; Radiotherapy Dosage; Treatment Outcome | 2010 |
Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Brachytherapy; Disease-Free Survival; Dose Fractionation, Radiation; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Incidence; Iridium Radioisotopes; Male; Middle Aged; Needles; Prostatic Neoplasms; Radiation Injuries; Radiography; Rectum; Relative Biological Effectiveness; Risk Factors; Time Factors; Tumor Burden | 2012 |
Evaluation of linear array MOSFET detectors for in vivo dosimetry to measure rectal dose in HDR brachytherapy.
Topics: Body Burden; Brachytherapy; Calibration; Equipment Design; Feasibility Studies; Female; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Quality Assurance, Health Care; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Rectum; Reproducibility of Results; Transistors, Electronic; Uterine Cervical Neoplasms | 2011 |
In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy.
Topics: Brachytherapy; Catheterization; Humans; Image Processing, Computer-Assisted; Iridium Radioisotopes; Liver; Magnetic Resonance Imaging; Male; Models, Statistical; Neoplasms; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results.
Topics: Aged; Aged, 80 and over; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy Dosage; Salvage Therapy; Treatment Outcome | 2012 |
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
Topics: Aged; Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Compartment Syndromes; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Grading; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Treatment Outcome; Urination Disorders | 2012 |
Solid state TL detectors for in vivo dosimetry in brachytherapy.
Topics: Brachytherapy; Calibration; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Rectum; Thermoluminescent Dosimetry | 2012 |
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Follow-Up Studies; Hormones; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2012 |
Gadolinium-153 as a brachytherapy isotope.
Topics: Anisotropy; Brachytherapy; Equipment Design; Gadolinium; Humans; Iridium Radioisotopes; Male; Monte Carlo Method; Photons; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radiotherapy Dosage; Scattering, Radiation | 2013 |
Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brachytherapy; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Iridium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Palliative Care; Prostatic Neoplasms; Radiotherapy Dosage; Rectal Neoplasms; Sigmoid Neoplasms; Time Factors; Tongue Neoplasms; Tonsillar Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms | 2002 |
Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation: initial Australian experience.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Erectile Dysfunction; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome | 2003 |
3D dose verification in 192Ir HDR prostate monotherapy using polymer gels and MRI.
Topics: Algorithms; Brachytherapy; Calibration; Dose-Response Relationship, Radiation; Gels; Glass; Humans; Imaging, Three-Dimensional; Iridium Radioisotopes; Magnetic Resonance Imaging; Male; Phantoms, Imaging; Polymers; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2003 |
In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer.
Topics: Brachytherapy; Calibration; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Thermoluminescent Dosimetry; Tomography, X-Ray Computed | 2003 |
The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Middle Aged; Palladium; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal | 2003 |
Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
Topics: Brachytherapy; Costs and Cost Analysis; Family Health; Feasibility Studies; Humans; Iridium Radioisotopes; Male; Occupational Exposure; Prostatic Neoplasms; Radiobiology; Radiology; Radiotherapy Dosage | 2002 |
Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Conformal; Rectum; Urinary Bladder | 2004 |
In regard to Anagnostopoulos et al.: In vivo thermoluminescence dosimetry dose verification of transperinal (192)Ir high dose rate brachytherapy using CT-based planning for the treatment of prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:1183-1191).
Topics: Brachytherapy; Copper; Humans; Iridium Radioisotopes; Lithium Compounds; Magnesium; Male; Phosphorus; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Thermoluminescent Dosimetry | 2004 |
Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Topics: Aged; Brachytherapy; Health Status; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Radiotherapy, Conformal; Surveys and Questionnaires | 2004 |
Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm.
Topics: Aged; Algorithms; Brachytherapy; Ferric Compounds; Humans; Iridium Radioisotopes; Male; Palladium; Pelvis; Prostate; Prostatic Neoplasms; Radioisotopes; Salvage Therapy; Tomography, X-Ray Computed | 2004 |
Dosimetric characterization of radioactive sources employed in prostate cancer therapy.
Topics: Brachytherapy; Computer Simulation; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Palladium; Prostatic Neoplasms; Radioisotopes; Radiometry; Radiotherapy, Computer-Assisted | 2004 |
[The recommendations of the International Commission on Radiological Protection (ICRP) for high-dose-rate brachytherapy and for permanent prostatic implants].
Topics: Adult; Brachytherapy; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Palladium; Prostatic Neoplasms; Radiation Injuries; Radiation Protection; Radioisotopes; Radiotherapy Dosage | 2004 |
GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
Topics: Brachytherapy; Contraindications; Dose Fractionation, Radiation; Humans; Iridium Radioisotopes; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Patient Selection; Prostatic Neoplasms; Radiation Injuries; Rectum; Salvage Therapy; Ultrasonography | 2005 |
Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy
Topics: Aged; Brachytherapy; Dose Fractionation, Radiation; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Severity of Illness Index; Urethra; Urinary Bladder; Urination Disorders | 2005 |
Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genito
Topics: Aged; Aged, 80 and over; Analysis of Variance; Brachytherapy; Combined Modality Therapy; Dose Fractionation, Radiation; Feasibility Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Urethra; Urination Disorders | 2005 |
192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Topics: Adenocarcinoma; Brachytherapy; Combined Modality Therapy; Dose-Response Relationship, Radiation; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Computer-Assisted | 2006 |
Optimization of dose distribution for HDR brachytherapy of the prostate using Attraction-Repulsion Model.
Topics: Algorithms; Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostate; Prostatic Neoplasms; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Rectum; Urethra; Urinary Bladder | 2006 |
Anatomy-based inverse optimization in high-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: comparison of incidence of acute genitourinary toxicity between anatomy-based inverse optimization
Topics: Aged; Aged, 80 and over; Brachytherapy; Dose Fractionation, Radiation; Female; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostate; Prostatic Neoplasms; Radiation Injuries; Radiography; Radiotherapy, Conformal; Rectum; Urethra; Urogenital System | 2006 |
A dosimetric comparison of 169Yb versus 192Ir for HDR prostate brachytherapy.
Topics: Biophysical Phenomena; Biophysics; Brachytherapy; Computer Simulation; Humans; Iridium Radioisotopes; Male; Monte Carlo Method; Prostatic Neoplasms; Radioisotopes; Radiotherapy Planning, Computer-Assisted; Ytterbium | 2005 |
Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Biopsy, Needle; Brachytherapy; Carcinosarcoma; Combined Modality Therapy; Follow-Up Studies; Humans; Immunohistochemistry; Iridium Radioisotopes; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Pelvic Exenteration; Prostate-Specific Antigen; Prostatic Neoplasms; Rectal Neoplasms; Time Factors; Treatment Outcome | 2006 |
Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Brachytherapy; Dose Fractionation, Radiation; Gastrointestinal Hemorrhage; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Rectal Diseases; Rectum | 2006 |
High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Dose Fractionation, Radiation; Gonadotropin-Releasing Hormone; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
Topics: Aged; Aged, 80 and over; Brachytherapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoadjuvant Therapy; Proctitis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Survival Analysis; Time Factors; Treatment Failure; Urogenital System | 2006 |
High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: technical and methodological aspects.
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostate; Prostatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Urethra | 2006 |
Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm.
Topics: Algorithms; Combined Modality Therapy; Computer Simulation; Humans; Iodine Radioisotopes; Iridium Radioisotopes; Male; Models, Biological; Prostatic Neoplasms; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2007 |
[How to select the treatment options in prostate cancer].
Topics: Brachytherapy; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Informed Consent; Iodine Radioisotopes; Iridium Radioisotopes; Male; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Radiotherapy, Conformal | 2007 |
[The role of brachytherapy in the therapeutic strategy of vesico-prostatic rhabdomyosarcoma in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Child; Child, Preschool; Combined Modality Therapy; Cystectomy; Humans; Infant; Iridium Radioisotopes; Male; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Rhabdomyosarcoma; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 1994 |
A nondivergent specification of the mean treatment dose in interstitial brachytherapy.
Topics: Biometry; Biophysical Phenomena; Biophysics; Brachytherapy; Humans; Iridium Radioisotopes; Male; Models, Biological; Prostatic Neoplasms; Radiotherapy Dosage | 1996 |
Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating.
Topics: Animals; Combined Modality Therapy; Dose-Response Relationship, Radiation; Hyperthermia, Induced; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiotherapy Dosage; Rats; Rats, Inbred Strains; Survival Analysis; Time Factors | 1996 |
Iridium 192 high-dose-rate brachytherapy--a useful alternative therapy for localized prostate cancer?
Topics: Adult; Aged; Brachytherapy; Carcinoma; Disease-Free Survival; Erectile Dysfunction; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Rate | 1997 |
Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland.
Topics: Dose-Response Relationship, Radiation; Humans; Iridium Radioisotopes; Male; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Ultrasonography | 1997 |
High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Topics: Aged; Brachytherapy; Dose Fractionation, Radiation; Feasibility Studies; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage | 1998 |
[Combined treatment of localized prostate cancer with HDR-Iridium 192 remote brachytherapy and external beam irradiation].
Topics: Aged; Aged, 80 and over; Brachytherapy; Disease-Free Survival; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Treatment Outcome | 1999 |
Feasibility study combining low dose rate (192)Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Feasibility Studies; Follow-Up Studies; Humans; Intraoperative Care; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Pelvic Bones; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Rectum; Seminal Vesicles; Ultrasonography, Interventional; Urethra | 2000 |
An independent dose-to-point calculation program for the verification of high-dose-rate brachytherapy treatment planning.
Topics: Algorithms; Brachytherapy; Humans; Iridium Radioisotopes; Male; Physical Phenomena; Physics; Prostatic Neoplasms; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Software; Tomography, X-Ray Computed | 2000 |
PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 85 grays to prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Brachytherapy; Cohort Studies; Data Interpretation, Statistical; Follow-Up Studies; Humans; Immunoenzyme Techniques; Iridium Radioisotopes; Kinetics; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Time Factors | 2001 |
[High-dose rate Iridium-192 brachytherapy with flexible applicator--a trial toward decrease of stress during treatment and improvement of quality of life].
Topics: Aged; Aged, 80 and over; Brachytherapy; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Stress, Psychological | 2001 |
[High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Topics: Aged; Aged, 80 and over; Brachytherapy; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage | 2001 |
Long-term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brachytherapy; Humans; Iridium Radioisotopes; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, High-Energy; Survival Analysis | 2001 |
Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
Topics: Aged; Brachytherapy; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Poisson Distribution; Prospective Studies; Prostatic Neoplasms; Radiation Oncology; Radiotherapy, Conformal; Treatment Failure | 2002 |
Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Humans; Iridium Radioisotopes; Lymph Node Excision; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Survival Rate | 1992 |
Temporary iridium-192 implant in the management of carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Brachytherapy; Humans; Iridium Radioisotopes; Male; Middle Aged; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1992 |
[High-dose-rate brachytherapy of prostatic carcinoma with iridium 192].
Topics: Aged; Brachytherapy; Carcinoma; Follow-Up Studies; Humans; Iridium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Computer-Assisted; Remission Induction | 1992 |
Iridium-192 brachytherapy in the treatment of cancer of the prostate.
Topics: Adenocarcinoma; Aged; Brachytherapy; Humans; Iridium Radioisotopes; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Radiography | 1991 |
External beam irradiation combined with the use of 192-iridium implants and radiofrequency-induced hyperthermia in the treatment of prostatic carcinoma.
Topics: Brachytherapy; Combined Modality Therapy; Humans; Hyperthermia, Induced; Iridium Radioisotopes; Male; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage | 1991 |
Iridium-192 implants in patients with large stage C prostate cancer.
Topics: Bone Neoplasms; Brachytherapy; Combined Modality Therapy; Humans; Iridium Radioisotopes; Lymphatic Metastasis; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Rate | 1991 |
Pelvic lymphadenectomy and transperineal interstitial implantation of IR 192 combined with external beam radiotherapy for bulky stage C prostatic carcinoma.
Topics: Adult; Aged; Brachytherapy; Combined Modality Therapy; Follow-Up Studies; Humans; Iridium Radioisotopes; Lymph Node Excision; Male; Middle Aged; Pelvis; Prostatic Neoplasms | 1989 |
The European experience: use of transrectal ultrasound in the diagnosis and management of prostate cancer.
Topics: Brachytherapy; Europe; History, 20th Century; Humans; Iridium Radioisotopes; Male; Palpation; Prostatic Neoplasms; Ultrasonography; Urology | 1987 |
Bilateral pelvic lymphadenectomy, iridium 192 template, and external beam therapy for localized prostatic carcinoma: complications and results.
Topics: Adenocarcinoma; Aged; Brachytherapy; Combined Modality Therapy; Humans; Iridium Radioisotopes; Lymph Node Excision; Male; Middle Aged; Pelvis; Postoperative Complications; Proctitis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage | 1988 |
Remote interstitial afterloading in cancer of the prostate: preliminary experience with the MicroSelectron.
Topics: Brachytherapy; Humans; Iridium Radioisotopes; Male; Prostatic Neoplasms; Radiation Protection | 1988 |
Curative treatment of carcinoma of the prostate with an association of external irradiation, iridium implant and lymphadenectomy.
Topics: Adenocarcinoma; Aged; Brachytherapy; Humans; Iridium Radioisotopes; Lymph Node Excision; Male; Prognosis; Prostatic Neoplasms | 1987 |